GlobeNewswire: Hyperion Therapeutics, Inc. Contains the last 10 of 80 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:34:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/03/06/713173/10123610/en/Hyperion-Therapeutics-to-Present-at-27th-Annual-ROTH-Conference.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics to Present at 27th Annual ROTH Conference2015-03-06T14:00:00Z<![CDATA[BRISBANE, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 27]]>https://www.globenewswire.com/news-release/2015/02/27/710802/10122388/en/Hyperion-Therapeutics-Observes-Rare-Disease-Day-2015.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Observes Rare Disease Day 20152015-02-27T13:00:00Z<![CDATA[BRISBANE, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today joins with patients and their families, caregivers, researchers, the biopharmaceutical industry and others in recognizing and supporting Rare Disease Day 2015. Observed annually on the last day of February, Rare Disease Day is observed in more than 80 nations and is led internationally by the European Organization of Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in the U.S. Hyperion is proud to support this effort to improve awareness and education of rare diseases.]]>https://www.globenewswire.com/news-release/2015/02/26/710463/10122084/en/Hyperion-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2014-Financial-Results.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results2015-02-26T21:05:00Z<![CDATA[UCD Product Portfolio Generates $113.6 Million for Fiscal Year 2014 and $30.8 Million in Net Sales During the Fourth Quarter of 2014]]>https://www.globenewswire.com/news-release/2015/02/25/709892/10122021/en/Hyperion-Therapeutics-to-Present-at-the-Cowen-and-Company-35th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference2015-02-25T21:45:00Z<![CDATA[BRISBANE, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Cowen and Company 35]]>https://www.globenewswire.com/news-release/2015/02/19/708146/10121087/en/Hyperion-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2014-Financial-Results-After-Market-on-February-26-2015.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results After Market on February 26, 20152015-02-19T21:00:00Z<![CDATA[BRISBANE, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2014 financial results after market closes on Thursday, February 26, 2015. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update, at 4:30 p.m. EST (1:30 p.m. PST).]]>https://www.globenewswire.com/news-release/2015/02/17/706749/10120445/en/Hyperion-Therapeutics-Enters-Into-Completion-of-Phase-III-Clinical-Trial-Option-and-Mutual-Release-Agreement-With-Clal-Biotechnology-Industries-and-Yeda-Research-and-Development-Co.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement With Clal Biotechnology Industries and Yeda Research and Development Company2015-02-17T06:00:00Z<![CDATA[BRISBANE, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) ("Hyperion") today announced that it has amicably resolved its disputes, and entered into a completion of phase III clinical trial, option and mutual release agreement (the "Agreement") with Clal Biotechnology Industries Ltd. (TASE:CBI) ("CBI") and Yeda Research and Development Company, Ltd. ("Yeda") regarding DiaPep277, a product candidate developed by Andromeda Biotech, Ltd., a company which Hyperion acquired from CBI in June 2014. ]]>https://www.globenewswire.com/news-release/2015/02/10/704890/10119427/en/Hyperion-Therapeutics-Initiates-Clinical-Study-to-Further-Evaluate-RAVICTI-R-in-Pediatric-Subjects-Under-Two-Years-of-Age-With-Urea-Cycle-Disorders.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Initiates Clinical Study to Further Evaluate RAVICTI(R) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders2015-02-10T14:00:00Z<![CDATA[BRISBANE, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the dosing of the first patient in its HPN-100-009 study in pediatric subjects under two years of age with urea cycle disorders (UCDs). This open-label study and post-marketing requirement is designed to assess the efficacy, safety and pharmacokinetics of RAVICTI and will enroll UCD patients who are newly diagnosed or being switched from sodium phenylbutyrate. Hyperion estimates that patients in the first two years of life account for 15-20% of all patients diagnosed with UCDs and approximately 10% of the total volume of phenylbutyrate used in the U.S.]]>https://www.globenewswire.com/news-release/2015/02/04/703160/10118279/en/Hyperion-Therapeutics-to-Present-at-the-2015-Leerink-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics to Present at the 2015 Leerink Global Healthcare Conference2015-02-04T21:00:00Z<![CDATA[BRISBANE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 2:40 p.m. EST. To access the live webcast and subsequent archived recording, please visit Hyperion's website at ]]>https://www.globenewswire.com/news-release/2015/01/12/696731/10115167/en/Hyperion-Therapeutics-Announces-Data-Published-in-Genetics-in-Medicine-Showing-Blood-Ammonia-and-Glutamine-as-Predictors-of-Hyperammonemic-Crises-in-Patients-With-Urea-Cycle-Disord.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Announces Data Published in Genetics in Medicine Showing Blood Ammonia and Glutamine as Predictors of Hyperammonemic Crises in Patients With Urea Cycle Disorders2015-01-12T14:25:00Z<![CDATA[BRISBANE, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the online publication in ]]>https://www.globenewswire.com/news-release/2014/12/18/692681/10112997/en/Hyperion-Therapeutics-Added-to-Nasdaq-Biotechnology-Index-NBI.html?f=22&fvtc=4&fvtv=16686Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI)2014-12-18T21:05:00Z<![CDATA[BRISBANE, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). The semi-annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.]]>